Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Background: The emergence of antifungal resistance threatens effective treatment of invasive fungal infection (IFI). Invasive candidiasis is the most common health care–associated IFI. We evaluated the activity of fluconazole (FLU) against 20 788 invasive isolates of Candida (37 species) collected from 135 medical centers in 39 countries (1997–2016). The activity of anidulafungin, caspofungin, and micafungin (MCF) was evaluated against 15 308 isolates worldwide (2006–2016). Methods: Species identification was accomplished using phenotypic (1997–2001), genotypic, and proteomic methods (2006–2016). All isolates were tested using reference methods and clinical breakpoints published in the Clinical and Laboratory Standards Institute documents. Results: A decrease in the isolation of Candida albicans and an increase in the isolation of Candida glabrata and Candida parapsilosis were observed over time. Candida glabrata was the most common non–C. albicans species detected in all geographic regions except for Latin America, where C. parapsilosis and Candida tropicalis were more common. Six Candida auris isolates were detected: 1 each in 2009, 2013, 2014, and 2015 and 2 in 2016; all were from nosocomial bloodstream infections and were FLU-resistant (R). The highest rates of FLU-R isolates were seen in C. glabrata from North America (NA; 10.6%) and in C. tropicalis from the Asia-Pacific region (9.2%). A steady increase in isolation of C. glabrata and resistance to FLU was detected over 20 years in the United States. Echinocandin-R (EC-R) ranged from 3.5% for C. glabrata to 0.1% for C. albicans and C. parapsilosis. Resistance to MCF was highest among C. glabrata (2.8%) and C. tropicalis (1.3%) from NA. Mutations on FKS hot spot (HS) regions were detected among 70 EC-R isolates (51/70 were C. glabrata). Most isolates harboring FKS HS mutations were resistant to 2 or more ECs. Conclusions: EC-R and FLU-R remain uncommon among contemporary Candida isolates; however, a slow and steady emergence of resistance to both antifungal classes was observed in C. glabrata and C. tropicalis isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although relatively low levels of resistance for most Candida species have been described, the outcomes for candidemia remain poor, as high levels of mortality (15%-50%) have been associated with candida infections7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this Review, we explore the molecular mechanisms that contribute to antifungal drug resistance, with a focus on Candida spp., the most common cause of fungal infections in humans7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measured
22 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“Sentinel surveillance programs designed to capture organisms and patient demographic data from representative sites spanning a larger geographical area and over a longer period of time serve to fill the gaps in time and space that are necessarily left by the more intensive and focused, yet intermittent, population-bas…”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“The burden of invasive fungal infections (IFIs) for patients and health care systems is difficult to measure [2, 12]; however, it is well recognized that IFIs are associated with high morbidity and mortality rates and elevated health care costs.”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Self-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Caspofungin, micafungin, and anidulafungin were approved for clinical use by the US Food and Drug Administration (FDA) in 2001, 2005, and 2006, respectively, and are now recommended as firstline agents for treating IC [50, 67].”
BackgroundCalderone, R. (2012) · ASM Press eBooks · Cited by 912
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citation
Research works printed but not linked: 6
- Pfaller, 2012, The epidemiology of invasive candidasis, 449
- CLSI, 2012, M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement
- CLSI, 2008, M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 3rd ed
- CLSI, 2016, M59. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed.
- Pfaller, 2007, Azole antifungal drug cross-resistance: mechanisms epidemiology, and clinical significance, J Invasive Fungal Infect, 1, 74
- Xisto, 2017, Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug, J Antimicrob Chemother, 72, 988
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Biofilm of Candida albicans : formation, regulation and resistance
Pereira, R., Santos Fontenelle, R. O., Brito, E. H. S., & Morais, S. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14949 · Cited by 368
Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens
Friedman, D. Z. P., & Schwartz, I. S. (2019) · Journal of Fungi · doi:10.3390/jof5030067 · Cited by 357
Molecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
“Further compounding this public health threat is the increased prevalence of inherently drug-resistant fungi, such as the emerging non-albicans Candida species, Candida auris and Candida glabrata 8 .”
Lass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Arastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272
Ahmad, S., & Alfouzan, W. (2021) · Microorganisms · doi:10.3390/microorganisms9040807 · Cited by 269
Candidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
Antimicrobial Peptides: a New Frontier in Antifungal Therapy
Buda De Cesare, G., Cristy, S. A., Garsin, D. A., & Lorenz, M. C. (2020) · mBio · doi:10.1128/mbio.02123-20 · Cited by 231
Costa-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
The importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Update on Candida krusei , a potential multidrug-resistant pathogen
Jamiu, A. T., Albertyn, J., Sebolai, O. M., & Pohl, C. H. (2020) · Medical Mycology · doi:10.1093/mmy/myaa031 · Cited by 211
Invasive candidiasis: current clinical challenges and unmet needs in adult populations
Soriano, A., Honore, P. M., Puerta-Alcalde, P., Garcia-Vidal, C., Pagotto, A., Gonçalves-Bradley, D. C., & Verweij, P. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad139 · Cited by 190
Invasive candidiasis in critical care: challenges and future directions
Logan, C., Martin-Loeches, I., & Bicanic, T. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06240-x · Cited by 180
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention
Holmes, C. L., Albin, O. R., Mobley, H. L. T., & Bachman, M. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01105-2 · Cited by 180
Diagnosis and Treatment of Invasive Candidiasis
Barantsevich, N., & Barantsevich, E. (2022) · Antibiotics · doi:10.3390/antibiotics11060718 · Cited by 178
Biofilm formation in medically important Candida species
Malinovská, Z., Čonková, E., & Váczi, P. (2023) · Journal of Fungi · doi:10.3390/jof9100955 · Cited by 167
Branco, J., Miranda, I. M., & Rodrigues, A. G. (2023) · Journal of Fungi · doi:10.3390/jof9010080 · Cited by 164
Chen, J., Tian, S., Han, X., Chu, Y., Wang, Q., Zhou, B., & Shang, H. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05543-0 · Cited by 159
Chu, Y., Li, M., Jin, J., Dong, X., Xu, K., Jin, L., Qiao, Y., & Ji, H. (2023) · Journal of Fungi · doi:10.3390/jof9020170 · Cited by 157
Combatting the evolution of antifungal resistance in Cryptococcus neoformans
Bermas, A., & Geddes‐McAlister, J. (2020) · Molecular Microbiology · doi:10.1111/mmi.14565 · Cited by 155
Arendrup, M. C., Arıkan-Akdağlı, S., Jørgensen, K. M., Barac, A. M., Steinmann, J., Toscano, C., Arsić-Arsenijević, V. S., Sartor, A., Lass‐Flörl, C., Hamprecht, A. G., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.08.001 · Cited by 153
Chakrabarti, A., & Sood, P. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001318 · Cited by 148
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
Identification of Drug Resistant Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01918 · Cited by 145
Antifungal Resistance: a Concerning Trend for the Present and Future
Hendrickson, J. A., Hu, C., Aitken, S. L., & Beyda, N. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0702-9 · Cited by 139
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 139
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
“%) despite available antifungal therapies (Pfaller et al., 2010; Pfaller et al., 2019).”
Adapting to survive: How Candida overcomes host-imposed constraints during human colonization
Alves, R. M. A., Barata-Antunes, C., Casal, M., Brown, A. J. P., Dijck, P. V., & Paiva, S. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008478 · Cited by 134
Candida auris Infection and Biofilm Formation: Going Beyond the Surface
Horton, M. V., & Nett, J. E. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00143-7 · Cited by 132
Candida auris Outbreaks: Current Status and Future Perspectives
Gaetano, S. D., Midiri, A., Mancuso, G., Avola, M. G., & Biondo, C. (2024) · Microorganisms · doi:10.3390/microorganisms12050927 · Cited by 124
Kim, H. Y., Nguyen, T. A., Kidd, S. E., Chambers, J., Alastruey‐Izquierdo, A., Shin, J.-H., Dao, A., Forastiero, A., Wahyuningsih, R., Chakrabarti, A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae042 · Cited by 123
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 122
Antifungal Resistance and the Role of New Therapeutic Agents
Logan, A., Wolfe, A. L., & Williamson, J. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00782-5 · Cited by 117
Xiao, M., Chen, S. C.-A., Kong, F., Xu, X.-L., Yan, L., Kong, H.-S., Fan, X., Hou, X., Cheng, J.-W., Zhou, M.-L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz573 · Cited by 115
Invasive candidiasis species distribution and trends, United States, 2009-2017
Ricotta, E. E., Lai, Y. L., Babiker, A., Strich, J. R., Kadri, S. S., Lionakis, M. S., Prevots, D. R., & Adjemian, J. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa502 · Cited by 114
Nine Things Genomics Can Tell Us About Candida auris
Chybowska, A. D., Childers, D. S., & Farrer, R. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00351 · Cited by 110
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“18,62,66 However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.”
BackgroundInfluentialHuman inborn errors of immunity underlying superficial or invasive candidiasis
Puel, A. (2020) · Human Genetics · doi:10.1007/s00439-020-02141-7 · Cited by 109
Ksiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
Posteraro, B., Torelli, R., Vella, A., Leone, P. M., Angelis, G. D., Carolis, E. D., Ventura, G., Sanguinetti, M., & Fantoni, M. (2020) · Journal of Fungi · doi:10.3390/jof6030163 · Cited by 107
Ambaraghassi, G., Dufresne, P. J., Dufresne, S. F., Vallières, É., Muñoz, J. F., Cuomo, C. A., Berkow, E. L., Lockhart, S. R., & Luong, M. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00884-19 · Cited by 102
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 100
Strategies to Prevent Transmission of Candida auris in Healthcare Settings
Ahmad, S., & Asadzadeh, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00451-7 · Cited by 100
Frei, A., Elliott, A. G., Kan, A. E., Dinh, H., Bräse, S., Bruce, A. E., Bruce, M. R. M., Chen, F., Humaidy, D., Jung, N., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00308 · Cited by 98
Arastehfar, A. A., Polat, S. H., Daneshnia, F., Pan, W., Hafez, A. I., Fang, W., Liao, W., Şahbudak-Bal, Z., Metin, D. Y., de Almeida, J. N., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.676177 · Cited by 94
Candida parapsilosis complex in the clinical setting
Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 94
Bilal, H., Shafiq, M., Hou, B., Islam, R., Khan, M. N., Khan, R. U., & Zeng, Y. (2022) · Virulence · doi:10.1080/21505594.2022.2123325 · Cited by 91
Martini, C., Torelli, R., de Groot, T., Carolis, E. D., Morandotti, G. A., Angelis, G. D., Posteraro, B., Meis, J. F. G. M., & Sanguinetti, M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00232 · Cited by 87
Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs
Arastehfar, A. A., Shaban, T., Zarrinfar, H., Roudbary, M., Ghazanfari, M., Hedayati, M. T., Sedaghat, A., İlkit, M., Najafzadeh, M. J., & Perlin, D. S. (2021) · Journal of Fungi · doi:10.3390/jof7040280 · Cited by 87
Commensalism and pathogenesis of Candida albicans at the mucosal interface
Schille, T. B., Sprague, J. L., Naglik, J. R., Brunke, S., & Hube, B. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01174-x · Cited by 87
O’Brien, C. E., Oliveira-Pacheco, J., Cinnéide, E. Ó., Haase, M. A. B., Hittinger, C. T., Rogers, T. R., Zaragoza, Ó., Bond, U., & Butler, G. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009138 · Cited by 86
The emerging threat antifungal-resistant Candida tropicalis in humans, animals, and environment
Lima, R., Ribeiro, F. D. C., Colombo, A. L., & de Almeida, J. N. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.957021 · Cited by 85
Ball, B., Langille, M. G. I., & Geddes‐McAlister, J. (2020) · mBio · doi:10.1128/mbio.01020-20 · Cited by 84
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Tóth, Z., Forgács, L., Locke, J. B., Kardos, G., Nagy, F., Kovács, R., Szekely, A., Borman, A. M., & Majoros, L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz390 · Cited by 82
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Self-citationAn overview of antimicrobial properties of kombucha
Nyiew, K.-Y., Kwong, P. J., & Yow, Y. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12892 · Cited by 82
Karkowska‐Kuleta, J., Kulig, K., Karnas, E., Zuba‐Surma, E. K., Woźnicka, O., Pyza, E., Kuleta, P., Osyczka, A., Rąpała‐Kozik, M., & Kozik, A. (2020) · Cells · doi:10.3390/cells9071722 · Cited by 82
In vitro antifungal activity of Thymus vulgaris essential oil nanoemulsion
Moazeni, M., Davari, A., Shabanzadeh, S., Akhtari, J., Saeedi, M., Morteza‐Semnani, K., Abastabar, M., Nabili, M., Moghadam, F. H., Roohi, B., et al. (2021) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2021.100452 · Cited by 81
A One Health approach to overcoming fungal disease and antifungal resistance
Woods, M., McAlister, J. A., & Geddes‐McAlister, J. (2023) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1610 · Cited by 80
Understanding the mechanisms of resistance to azole antifungals in Candida species
Li, Y., Hind, C. K., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf106 · Cited by 77
Analysis of Candida auris fungemia at a single facility in Kenya
Adam, R. D., Revathi, G., Okinda, N., Fontaine, M., Shah, J., Kagotho, E., Castanheira, M., Pfaller, M. A., & Maina, D. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.06.001 · Cited by 76
Self-citationMolecular Methods for the Diagnosis of Invasive Candidiasis
Camp, I., Spettel, K., & Willinger, B. (2020) · Journal of Fungi · doi:10.3390/jof6030101 · Cited by 75
Fluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
Keighley, C., Cooley, L., Morris, A. J., Ritchie, D., Clark, J. E., Boan, P., & Worth, L. J. (2021) · Internal Medicine Journal · doi:10.1111/imj.15589 · Cited by 73
The fitness costs and benefits of trisomy of each Candida albicans chromosome
Yang, F., Todd, R. T., Selmecki, A., Jiang, Y.-Y., Cao, Y.-B., & Berman, J. (2021) · Genetics · doi:10.1093/genetics/iyab056 · Cited by 72
Interactions between Candida albicans and the resident microbiota
Li, H., Miao, M., Jia, C., Cao, Y.-B., Yan, T., Jiang, Y., & Yang, F. J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.930495 · Cited by 72
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 69
Self-citationDebta, P., Swain, S. K., Sahu, M. C., Abuderman, A., Alzahrani, K. J., Banjer, H. J., Qureshi, A. A., Bakri, M. M. H., Sarode, G. S., Patro, S., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148510 · Cited by 69
Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68
Self-citationde Jong, A. W., Dieleman, C., Carbia, M., Tap, R. M., & Hagen, F. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.03220-20 · Cited by 67
Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 66
Ning, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2153086 · Cited by 63
“Other common Candida species, including C. albicans, C. tropicalis, C. glabrata and C. lusitaniae, generally were most susceptible to micafungin among the three echinocandins, while C. krusei and C. pelliculasa most susceptible to anidulafungin [41,43,44,47].”
Sharma, C., & Kadosh, D. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011190 · Cited by 63
Yang, F., Scopel, E. F. C., Li, H., Sun, L.-L., Kawar, N., Cao, Y.-B., Jiang, Y.-Y., & Berman, J. (2023) · mBio · doi:10.1128/mbio.00227-23 · Cited by 62
Castanheira, M., Deshpande, L. M., Davis, A. P., Carvalhaes, C. G., & Pfaller, M. A. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.05.004 · Cited by 62
Self-citationInvasive fungal infections in acute and chronic liver impairment: A systematic review
Lahmer, T., Pietrobom, P. M. P., Schmid, R. M., & Colombo, A. L. (2021) · Mycoses · doi:10.1111/myc.13403 · Cited by 61
Beardsley, J., Kim, H. Y., Dao, A., Kidd, S. E., Alastruey‐Izquierdo, A., Sorrell, T. C., Tacconelli, E., Chakrabarti, A., Harrison, T. S., Bongomin, F., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae041 · Cited by 61
Sui, Y., Ansari, M. F., Fang, B., Zhang, S., & Zhou, C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113557 · Cited by 61
Tunicamycin Potentiates Antifungal Drug Tolerance via Aneuploidy in Candida albicans
Yang, F., Gritsenko, V., Slor Futterman, Y., Gao, L., Zhen, C., Lu, H., Jiang, Y.-Y., & Berman, J. (2021) · mBio · doi:10.1128/mbio.02272-21 · Cited by 59
“4%) (4), patient treatment failures are quite high (.”
BackgroundShivarathri, R., Jenull, S., Stoiber, A., Chauhan, M., Mazumdar, R., Singh, A., Nogueira, F., Kuchler, K., Chowdhary, A., & Chauhan, N. (2020) · mSphere · doi:10.1128/msphere.00973-20 · Cited by 59
König, A., Hube, B., & Kasper, L. (2020) · Toxins · doi:10.3390/toxins12080469 · Cited by 59
Arastehfar, A. A., Daneshnia, F., Polat, S. H., İlkit, M., Yaşar, M., Polat, F., Metin, D. Y., Dökümcü, Z., Pan, W., Hagen, F., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa419 · Cited by 59
Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018
Won, E. J., Choi, M. J., Kim, M., Yong, D., Lee, W. G., Uh, Y., Kim, T. S., Byeon, S. A., Lee, S. Y., Kim, S. H., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2703.203482 · Cited by 59
Arastehfar, A., Daneshnia, F., Cabrera, N., Penalva-Lopez, S., Sarathy, J., Zimmerman, M., Shor, E., & Perlin, D. S. (2023) · Nature Communications · doi:10.1038/s41467-023-36882-6 · Cited by 58
Roles of Hsp90 in Candida albicans morphogenesis and virulence
Robbins, N., & Cowen, L. E. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102351 · Cited by 58
Mamali, V., Siopi, M., Charpantidis, S., Samonis, G., Tsakris, A., Vrioni, G., & on behalf of the Candi-Candi Network (2022) · Journal of Fungi · doi:10.3390/jof8020116 · Cited by 57
Fungi in the indoor air of critical hospital areas: a review
Belizário, J. A., Lopes, L. G., & Pires, R. H. (2021) · Aerobiologia · doi:10.1007/s10453-021-09706-7 · Cited by 57
Bédard, C., Gagnon‐Arsenault, I., Boisvert, J., Plante, S., Dubé, A. K., Pageau, A., Fijarczyk, A., Sharma, J., Maroc, L., Shapiro, R. S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01819-2 · Cited by 56
Billamboz, M., Fatima, Z., Hameed, S., & Jawhara, S. (2021) · Microorganisms · doi:10.3390/microorganisms9030634 · Cited by 56
Fan, X., Dai, R.-C., Zhang, S., Geng, Y.-Y., Kang, M., Guo, D.-W., Mei, Y.-N., Pan, Y.-H., Sun, Z.-Y., Xu, Y.-C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43380-2 · Cited by 55
Asadzadeh, M., Mokaddas, E., Ahmad, S., Abdullah, A. A., de Groot, T., Meis, J. F., & Shetty, S. A. (2022) · Mycoses · doi:10.1111/myc.13419 · Cited by 55
Castelo‐Branco, D. D. S. C. M., Lockhart, S. R., Chen, Y., Santos, D. A., Hagen, F., Hawkins, N. J., Lavergne, R., Meis, J. F. G. M., Pape, P. L., Rocha, M. F. G., et al. (2021) · Mycoses · doi:10.1111/myc.13404 · Cited by 55
Díaz-García, J., Gómez, A., Alcalá, L., Reigadas, E., Sánchez‐Carrillo, C., Pérez‐Ayala, A., de la Pedrosa, E. G., González‐Romo, F., Amador, P. M., Cuétara, M. S., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00710-22 · Cited by 55
Trevijano-Contador, N., Torres-Cano, A., Carballo-González, C., Puig-Asensio, M., Martín-Gómez, M. T., Jiménez-Martínez, E., Romero, D., Nuvials, F. X., Olmos-Arenas, R., Moretó-Castellsagué, M. C., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac605 · Cited by 54
Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey
Kutlu, M., Kutlu, S. S., Çavuş, S. A., Öztürk, Ş. B., Tasbakan, M. I., Özhak, B., Kaya, O., Kutsoylu, O. Ö. E., Akar, Ş. Ş., Turhan, Ö., et al. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04394-0 · Cited by 54
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N.
- Affiliations
- University of Iowa (US)
- The University of Adelaide (AU)
- JMI Laboratories (US)
- Corresponding author
- Pfaller, Michael A
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03
- Volume
- 6
- Issue
- Supplement_1
- Pages
- S79-S94
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC6419901
- OpenAlex
- W2922388167
- Semantic Scholar
- b99f36f4463b9afe6d2a0ab52eebb3f5e726f4c0
- Cited by
- 825
- References
- 114
- Citations by year
- 2026: 92 · 2025: 129 · 2024: 133 · 2023: 141 · 2022: 94 · 2021: 108 · 2020: 104 · 2019: 24
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- JMI Laboratories
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- invasive candidiasis, Candida species, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida auris, micafungin resistance, caspofungin, anidulafungin, Candida species distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.